Alkermes Plc · NASDAQ:ALKS
Alkermes — Q1 2020 Earnings Presentation
15 slides from Alkermes's earnings presentation, Apr 29, 2020
Slide 1: First Quarter 2020 Financial Results & Business Update
First Quarter 2020 Financial Results & Business Update April 29, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Introduction Sandy Coombs, VP, Investor Relations COVID-19 Update Richard Pops, Chief Executive Officer Q1 2020 Commercial Review Todd Nichols, SVP, Sales and Marketing Q1 2020 Financial Results; 2020 Financial Outlook Jim Frates, Chief Financial Officer Business Update Richard Pops, Chief Executive
Slide 4: Operational Priorities in Response to COVID-19
Operational Priorities in Response to COVID-19 Protecting the Well-Being of Employees Remote work policy for those who can carry out responsibilities remotely Virtual customer engagements for field-based personnel Additional employee safety precautions in labs and manufacturing facilities Business C
Slide 5: Net Sales From Proprietary Commercial Medicines
Net Sales From Proprietary Commercial Medicines Proprietary Commercial Product Net Sales ($M)
Slide 6: VIVITROL Performance
VIVITROL® Performance Q1 year-over-year net sales growth of 14% to $78.8M, driven by unit growth of 13% Gross-to-net deductions: 49% in Q1’20, compared to 49% in Q1’19 and 48% in Q4’19 Sequential decrease in net sales driven by seasonal inventory drawdown in Q1’20 VIVITROL Quarterly Net Sales ($M)
Slide 7: ARISTADA Performance
ARISTADA® Performance Q1 year-over-year net sales growth of 68% to $51.0M, driven by unit growth of 70% Growth reflects strong underlying demand and the impact of the significant inventory drawdown in Q1’19 Gross-to-net deductions: 52% in Q1’20, compared to 49% in Q1’19 and 51% in Q4’19 Sequential d
Slide 8: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q1 year-over-year growth of 43% on TRx months of therapy (MOT) basis Compared to overall atypical long-acting injectable (LAI) market growth of 13% Q1 sequential growth of 7% on TRx MOT basis Compared to overall atypical LAI market growth of 2% Market share: NRx
Slide 9: Adapted Commercial Strategy in Response to COVID-19
Adapted Commercial Strategy in Response to COVID-19 Transitioned customer engagement strategy to a virtual model Advance digital capabilities while continuing to support broad access to VIVITROL®, ARISTADA® and ARISTADA INITIO® Dedicated to supporting evolving needs of healthcare providers and patie
Slide 10: Q1 2020 Financial Results Summary
Q1 2020 Financial Results Summary
Slide 11: First Quarter 2020 Revenue Summary
First Quarter 2020 Revenue Summary In millions, except % Q1’20 Q1’19 ∆ Q1’20 vs. Q1’19 VIVITROL® $78.8 $69.2 14% ARISTADA® $51.0 $30.3 68% Manufacturing & Royalty Revenue $116.3 $108.9 7% R&D Revenue $0.2 $14.7 (98%)* Total Revenue $246.2 $223.1 10% Amounts in the table above do not sum due to round
Slide 12: 2020 Financial Outlook
2020 Financial Outlook Well-positioned financially with sufficient capital and liquidity to advance business objectives Cash, cash equivalents and total investments of $549.7M at March 31, 2020 Cash on hand significantly exceeded the company’s total debt outstanding of $276.6M under its term loan, w
Slide 13: Research and Development Pipeline: Status and Priorities
ALKS 3831 ALKS 4230 Selective HDAC Inhibitors Research and Development Pipeline: Status and Priorities Prescription Drug User Fee Act (PDUFA) target action date: Nov. 15, 2020 Preparing for Advisory Committee meeting anticipated in Fall 2020 Patient enrollment ongoing in ARTISTRY-1 and ARTISTRY-2 Ac
Slide 14: 2020 Key Objectives
2020 Key Objectives Drive growth of VIVITROL® and ARISTADA® through commercial execution Prepare for potential launch of ALKS 3831 for the treatment of schizophrenia and the treatment of bipolar I disorder Advance the development of ALKS 4230 in oncology
Slide 15: www.alkermes.com
www.alkermes.com